Abstract: Objective：To evaluate the clinical efficacy and economic of guanxinjing capsule for angina pectoris of coronary heart disease， and to provide reference for drug payment and clinical treatment. Methods：By prospective， randomized design，420 patients with angina pectoris of coronary heart disease from 11 hospitals were selected as subjects according to the sale distribution of guanxinjing capsule in district and hospital， 313 cases of experimental group (guanxinjing capsule group) and 107 cases of control group (shenshao capsule group)， and the course of treatment in the two groups were 4 weeks. The efficacy of angina pectoris symptom， TCM symptom， nitroglycerin reduction rate， electrocardiogram efficiency， Duck score improvement and exercise duration improvement were taken as the curative index. The economic analysis method was cost-effect analysis， and drug price was the single factor sensitive analysis. Results：The curative effect of angina pectoris and TCM syndromes were better than that of the control group. Nitroglycerin reduction rate， ECG efficiency， duck score improved and duration of exercise to improve the efficacy of the two groups. The results of cost-effectiveness analysis showed that guanxinjing capsule was more economical and the results of sensitivity analysis did not change the basic analysis results.Conclusion：Guanxinjing capsules in the treatment of angina pectoris of coronary heart disease efficacy， clinical safety， its economy is better than shenshao capsule.